Trial Profile
Can Ki-67 Predict Acromegaly Response to Pegvisomant?
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Aug 2015
Price :
$35
*
At a glance
- Drugs Pegvisomant (Primary)
- Indications Acromegaly; Pituitary adenoma
- Focus Pharmacodynamics
- 24 Aug 2015 New trial record